Snapshot from Sep 03, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Regeneron melanoma trial failure class action
Regulatory securities class action

Regeneron melanoma trial failure class action

Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Sep 02, 2026

Sentiment
-60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The failed trial and subsequent lawsuit have negatively impacted Regeneron's stock price and market capitalization, with an $11 billion loss in market cap. The litigation could result in significant financial penalties and further reputational damage for the company.

Pharmaceuticals Biotechnology
Event Summary

Regeneron Pharmaceuticals disclosed on May 15, 2026 that its Phase 3 trial of Fianlimab in combination with Libtayo for first-line metastatic or locally advanced melanoma failed to meet the primary endpoint of progression-free survival. The announcement caused an $11 billion market cap wipeout. Regeneron had previously expressed optimism about the trial, calling it a potential blockbuster, and had altered the trial protocol in late 2025 without timely disclosure. Hagens Berman filed a securities class action lawsuit on behalf of investors who purchased Regeneron stock between August 1, 2025 and May 15, 2026, alleging false and misleading statements. The lead plaintiff deadline is September 14, 2026.

Key Actions
100 Regeneron Pharmaceuticals disclosed trial failure
80 Regeneron Pharmaceuticals announced trial expansion
70 Hagens Berman filed lawsuit Regeneron Pharmaceuticals
Entities Involved
stock
Regeneron Pharmaceuticals
Regeneron is the defendant in the class action lawsuit. The failed trial and alleged misleading statements have caused a severe drop in its stock price and market value, and the company faces potential legal and financial consequences.
Importance 100.0 Sentiment -80.0
priv
Hagens Berman
Hagens Berman is the law firm that filed the class action lawsuit against Regeneron. The firm is investigating the claims and seeking lead plaintiffs, which could enhance its reputation and generate fees if successful.
Importance 70.0 Sentiment 20.0
per
Reed Kathrein
Reed Kathrein is the Hagens Berman partner leading the investigation. His role is to represent investors and pursue the lawsuit, which could bring professional recognition.
Importance 40.0 Sentiment 10.0
govactor
United States — United States Securities and Exchange Commission
The SEC is mentioned in relation to its whistleblower program, which could incentivize individuals to provide information about Regeneron's conduct. The SEC may also investigate the alleged securities violations.
Importance 30.0 Sentiment 0.0
Relationships
Hagens Berman related ↔ Reed Kathrein
Hagens Berman securities litigator ↔ United States — United States Securities and Exchange Commission Hagens Berman is a national class-action law firm that frequently files securities fraud lawsuits against corporations,
Reed Kathrein securities litigator ↔ United States — United States Securities and Exchange Commission Reed Kathrein is a partner at Hagens Berman who specializes in securities fraud class action lawsuits, representing inve
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.